Ferrous sulfate 50 mg daily in pregnant women with a hemoglobin (Hb) ≥13.2 g/dL significantly increased the rate of small-for-gestational-age births and the number of women with a hypertensive disorder, compared with a group of pregnant women receiving placebo (15.7% vs. 10.3%, respectively, P=0.035, and 2.7% vs. 0.8%, respectively, P=0.05).
Ferrous sulfate 50 mg daily in pregnant women with a hemoglobin (Hb) ≥13.2 g/dL significantly increased the rate of small-for-gestational-age births and the number of women with a hypertensive disorder, compared with a group of pregnant women receiving placebo (15.7% vs. 10.3%, respectively, P=0.035, and 2.7% vs. 0.8%, respectively, P=0.05).
The findings come from researchers in Iran who conducted a randomized, double-blind, placebo-controlled trial involving 727 expectant women. As an accompanying editorial points out, while routine iron supplementation is important in the developing world, it should be prescribed selectively for nonanemic women having normal pregnancies in the developed world.
Ziaei S, Norrozi M, Faghihzadeh S, et al. A randomized placebo-controlled trial to determine the effect of iron supplementation on pregnancy outcome in pregnant women with haemoglobin ≥ 13.2 g/dl. BJOG. 2007;114:684-688.
SART data indicates rise in IVF use in 2022
April 24th 2024Dive into the latest statistics from the Society for Assisted Reproductive Technology, revealing a 6% increase in in vitro fertilization cycles and a surge in egg freezing, amidst a landscape of rising fertility service demand and evolving clinical practices.
Read More
Hyperoxygenation use not linked to neonatal outcomes
April 23rd 2024Recent research evaluated the impact of maternal hyperoxygenation on neonatal Apgar scores, revealing no significant enhancement in outcomes among women with pathologic fetal heart rate tracing and suggesting limited efficacy of hyperoxygenation therapy in this context.
Read More